LOGIN  |  REGISTER
Terns Pharmaceuticals

Becton Dickinson to Announce Financial Results for its Third Quarter of Fiscal 2025

May 12, 2025 | Last Trade: US$171.38 0.93 -0.54

FRANKLIN LAKES, N.J., May 12, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, August 7, 2025 to discuss the Company's financial results for its third quarter of fiscal year 2025, which ends on June 30, 2025, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation materials that will include summary financial information for the quarter.  The news release and related presentation materials will be made available at www.bd.com/investors.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson

Contacts:

Media:
Troy Kirkpatrick
VP, Public Relations
858.617.2361
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investors:
Adam Reiffe
Sr. Director, Investor Relations
201.847.6927  
This email address is being protected from spambots. You need JavaScript enabled to view it.     

 
Astria Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page